Liquid Biopsy Technology
Visit product site at:
OncoDiscover Liquid Biopsy Technology is the first indegeneously developed technology to receive ‘MD-9: License to Manufacture for Sale or for Distribution of Class C or Class D medical device’ for a non-predicate device in India under new Medical Device Rules (MDR 2017).
About 12.7 million cancer cases and 7.6 million cancer deaths are estimated to have occurred in 2008 worldwide, with 56% of the cases and 64% of the deaths in the economically developing world (Ref: GLBOCAN 2008). Almost 90% Cancer deaths are due to metastasis (spread of cancer to other parts of body) which is aided by tumour cells that break away from the primary tumour and move through the lymphatic system to reach distal organs. These cells are known as Circulating Tumor Cells (CTC) and act as seeds for cancer metastasis and secondary tumour growth.
Actorius Innovations and Research Pvt Ltd has developed a proprietary technology, for detection and enumeration of circulating tumour cells in peripheral blood, called the OncoDiscover Liquid Biopsy Technology. This platform is designed for specific targeting, rapid isolation and high-resolution imaging of cancer cells. OncoDiscover is a novel and efficient platform for detection of Circulating Tumour Cells (CTC) from peripheral blood of cancer patient.
This test can be used in defined intervals along with other clinical parameters to assess the success of therapy given to patient. Periodic monitoring of CTCs can also help in detecting metastasis earlier compared to routine imaging methods.